Symposium ーEnglish Sessionー
- Broad look at immunity, inflammation, and metabolism involving the digestive organ crosstalk
Living organisms comprise organ systems, each with their own unique regulatory mechanisms that generate complex in vivo responses. All these systems include intricate regulatory mechanisms around the organs, such as those found between the liver, pancreas, biliary tract, and gastrointestinal tract and the brain and autonomic nervous system. These are also found between the heart, kidneys, and even among muscles and bone marrow. Recent advances have led to a detailed understanding of the basic physiological functions of these organ systems and organs within homeostatic or regulatory mechanisms. Consequently, interdisciplinary studies encompassing areas including metabolism, intestinal bacteria, immunology, tissue microenvironment, extracellular vesicles, imaging, and multi-omics have revealed interorgan communication networks that considerably facilitate drug discovery and development. In this session, our primary focus will be on organs within the digestive system while also addressing those involved in immunity, inflammation, metabolism, and the nervous system. We will provide an overview and further discuss the latest findings spanning various organs and interdisciplinary fields, without limiting ourselves to a specific organ or academic field.
- Recent Advances in Minimally Invasive Endoscopic Treatment for Gastrointestinal Tumors
More than 20 years after the development of endoscopic submucosal dissection (ESD), endoscopic treatment is becoming more sophisticated as the development of devices and techniques. ESD of the duodenum, previously considered very high-risk, has been reported its improved outcomes, mainly by high-volume centers. Dissection in the proper muscular layer and even full thickness resection is now also being performed. There has also been significant progress in protection of wound by endoscopic suturing and covering material those enable challenging procedures described above. Furthermore, multidisciplinary treatment combining endoscopic therapy and chemoradiotherapy is being attempted. In this session, we would like to discuss about the cutting edge of endoscopic treatment for gastrointestinal tumors.
- Systemic therapies for advanced hepatocellular carcinoma
Combination immunotherapies, including atezolizumab + bevacizumab and durvalumab + tremelimumab, are currently employed as 1st line systemic treatments for advanced hepatocellular carcinoma. The treatment of advanced hepatocellular carcinoma is regarded as having reached a major turning point, because data from ongoing clinical trials will soon be published. Findings regarding the clinicopathological background of hepatocellular carcinoma, biomarkers, the cancer microenvironment, and other topics relevant to the selection and effectiveness of combination immunotherapy have been compiled. However, various issues remain unresolved, such as establishing effective treatment sequences after combination immunotherapy, identifying strategies for conversion treatment to cure hepatocellular carcinoma in responded cases, and elucidating the pathology of immune-related adverse events and their effective management. To address the above issues, the present symposium will feature presentations from a wide range of perspectives to contribute to future treatment and research on systemic therapy for advanced hepatocellular carcinoma and further discussions, including future prospects.
- Current Status and Future Prospects for Management of Acute and Chronic Pancreatitis
Over the past 30 years, the treatment outcomes for both acute and chronic pancreatitis have improved significantly. The fatality rate for severe cases of acute pancreatitis has dropped from 30% to 6%, with notable improvements in early stage fatality rates. Moreover, the application of minimally invasive treatments for late-stage infectious complications has enhanced treatment outcomes. In the context of chronic pancreatitis, the concept of early chronic pancreatitis has been introduced, and the effectiveness and limitations of endoscopic treatment, and surgery have been clarified. On the other hand, several challenges remain for acute pancreatitis. Including the development and implementation of additional treatments during the early stages of disease onset, determination of the optimal timing for therapeutic interventions in infectious complications, and the appropriate application of each treatment modality. Challenges in chronic pancreatitis include establishing diagnostic methods for early chronic pancreatitis and developing treatments that focus on improving the overall physical state, including the prevention of carcinogenesis. Furthermore, the widespread adoption of established treatments remains a significant issue for both acute and chronic pancreatitis. In this symposium, we will discuss the current status and future prospects of pancreatitis managements limited to these issues.
The14th International Forum of The Japanese Society of Gastroenterology
Advances in gastrointestinal and hepato-pancreato-biliary immune-mediated inflammatory diseases
- Advances in autoimmune liver disease
- Advances in immune-related pancreaticobiliary disease
- Advances in immune-related adverse event
- Advances in inflammatory bowel disease
The 5th JSGE Asian Session
Open a new window for diagnosis and treatment of pancreatobiliary diseases
The 17th JSGE-UEG Rising Stars Session
The 20th JSGE-AGA Joint Meeting
The Frontiers of Gut‒Brain Interaction